MetaVia Completes Last Patient Visit In Extended 24-Week Phase 1 Part 3A Study Of DA-1726
Encouraging Preliminary Safety and Tolerability Observations in Part 3A Supported Decision to Extend Treatment from 16 to 24 Weeks
Last updated: 2026-11-17 21:07:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
MetaVia Inc. (MTVA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.25, with a market capitalization of $8.56M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.97 to $13.42. This page covers its latest market performance, valuation, price trends and company information.
$8.56M | |
$1.23 | |
$1.37 | |
$1.19 | |
$1.21 | |
92.35K | |
114.21K | |
-- | |
$13.42 | |
$0.97 | |
-- | |
-- |
MetaVia Inc. (MTVA) is trading at $1.25 in after-hours trading as of 2026-11-17 21:05:00, up 0.08% ($0.00) from the regular-session close of $1.25.
After-hours trading shows how investors are pricing MTVA after the regular session closes. The current after-hours price is near the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, MetaVia Inc. (MTVA) moved from $1.43 to $1.25, representing a decline of 12.66% ($0.18).
The stock traded between $1.09 and $1.78 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 262.77 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 2.3%
MTVA is currently trading at $1.25, placing it 2.3% of the way from its 52-week low of $0.97 to its 52-week high of $13.42. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
MetaVia Inc is a clinical-stage biotechnology company focused on developing treatments for liver-related cardiometabolic diseases. Its product pipeline includes DA-1726, an oxyntomodulin analogue that acts as a dual GLP-1 and glucagon receptor agonist, being developed for metabolic and alcohol-associated liver diseases. The company is also developing vanoglipel (DA-1241), a GPR119 agonist, in combination with resmetirom for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 8 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to MetaVia Inc. and MTVA stock.
Encouraging Preliminary Safety and Tolerability Observations in Part 3A Supported Decision to Extend Treatment from 16 to 24 Weeks
MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming liver-related cardiometabolic diseases, today announced positive preclinical data from a head-to-head study comparing DA-1726, a
MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.73) by 5.48 percent. This is a 55.19 percent increase over losses of $(1.54) per share from the same
MetaVia reports positive Phase 1 data showing that once-weekly DA-1726 significantly reduces serum uric acid and liver fat.
Eligible investors can buy real shares of MetaVia Inc. (MTVA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to MTVA, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between MTVA shares and USD.
MTVA Shares to USD
1.00 MTVA shares = 1.249 USD
Calculations are estimates based on the latest available price and are for reference only.